David A. Siegel Terns Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 32,600 shares of TERN stock, worth $191,036. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,600
Previous 28,300
15.19%
Holding current value
$191,036
Previous $192,000
41.15%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TERN
# of Institutions
167Shares Held
78.3MCall Options Held
580KPut Options Held
454K-
Orbimed Advisors LLC San Diego, CA7.56MShares$44.3 Million1.49% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$40.4 Million8.42% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.22MShares$36.5 Million4.41% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$32.7 Million1.71% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$24.1 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $220M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...